– USA, NC – Polarean Imaging plc (LON: POLX), the medical imaging technology company today announced the appointment of current Non-Executive Director, Ken West as the new Chairman of the Board of Directors, effective immediately, succeeding Jonathan Allis who is retiring from the Board.
The company also announced the appointment of Dan Brague to its Board as a Non-Executive Director.
Dan Brague will also join the Remuneration Committee as its Chairman.
About Daniel Myron Brague
Dan is a highly accomplished executive leader focused on enterprise growth, business turnaround, and value creation. With over 20 years of experience in the global diagnostic imaging industry, Dan has a proven track record in strategy and company vision, P&L management, sales growth, and product innovation. He has a broad background in pharmaceutical companies, most recently as the North America CEO of Curium Pharma, the world’s largest nuclear medicine company.
About Polarean
The Company and its wholly-owned subsidiary, Polarean, Inc. are revenue-generating, investigational drug-device combination companies operating in the high-resolution medical imaging research space.
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specializes in the use of hyperpolarised Xenon gas as an imaging agent to visualize ventilation. 129Xe gas is currently being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream.
In October 2020, the Group submitted a New Drug Application to the FDA for hyperpolarised 129Xe used to evaluate the pulmonary function and to visualize the lung using MRI. The Group received a complete response letter on 6 October 2021.
The Group operates in an area of significant unmet medical need and the Group’s technology provides a novel investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform. The annual economic burden of pulmonary disease in the US is estimated to be over US$ 150 billion.
For more information: https://polarean.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.